<DOC>
	<DOCNO>NCT02772679</DOCNO>
	<brief_summary>The purpose study assess safety Tregs + IL-2 survival Tregs patient recent onset T1DM receive infusion autologous Tregs + IL-2 .</brief_summary>
	<brief_title>T1DM Immunotherapy Using Polyclonal Tregs + IL-2</brief_title>
	<detailed_description>The investigator hypothesize ex vivo expand human autologous CD4+CD127lo/-CD25+ polyclonal regulatory T cell ( Polyclonal Tregs ) plus Interleukin-2 ( IL-2 ) administer patient Type 1 Diabetes Mellitus ( T1DM ) safe biologically active . A Phase I trial cellular therapy plus IL-2 lead way Phase II trial test efficacy base preservation C-peptide , reduce exogenous insulin requirement improve glycemic control . This Phase I safety/dosing study Polyclonal Tregs + IL-2 patient T1DM . The Tregs expand use establish protocol utilizing anti-CD3/anti-CD28 bead plus IL-2 . The study involve 3 dose cohort 4 T1DM patient . The primary objective study assess safety Tregs + IL-2 survival Tregs patient recent onset T1DM receive infusion autologous Tregs + IL-2 . The study also assess potential effect Tregs beta cell function autoimmune response . Subjects receive Polyclonal Tregs dose 50x106 , 350x106 1x109 cell . The dose Tregs select base combination consideration manufacture capacity , predict efficacious dose , available safety data Treg product currently clinical trial . The IL-2 dose 1x106 IU subcutaneously , give daily 5 consecutive day completion cell infusion 1 month . This dose base recent study Klatzmann et al . T1DM , dose find effective selective Treg expansion , well tolerate , without acute decline beta cell function ( Rosenzwajg et al. , 2015 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>1 . Diagnosis T1DM within &gt; 3 &lt; 24 month day 0 accord American Diabetes Association standard criterion . 2 . 18 45 year age day screen visit . 3 . Positive least one islet cell autoantibody ( glutamate decarboxylase ; insulin , obtain within 10 day onset insulin therapy ; ICA 512antibody ; and/or ZnT8 ) . 4 . Peak stimulate Cpeptide level &gt; 0.2 pmol/mL ( 0.6 ng/ml ) follow MMTT . 5 . Weight &gt; 40 kg 6 . Adequate venous access support blood draw 5 mls/kg maximum 400 ml whole blood later infusion investigational therapy 1 . Hemoglobin &lt; 10.0 g/dL ; leukocytes &lt; 3,000/μL ; neutrophil &lt; 1,500/μL ; lymphocyte &lt; 800μL ; platelet &lt; 100,000/μL 2 . Any sign significant chronic active infection ( e.g. , hepatitis , tuberculosis , EBV , CMV , toxoplasmosis ) , screen laboratory evidence consistent significant chronic active infection ( positive HIV , PPD , HBsAg ) . 3 . Anticipated ongoing use diabetes medication insulin affect glucose homeostasis , metformin , sulfonylurea , thiazolidinediones , glucagonlike peptide 1 ( GLP1 ) mimetics , dipeptidyl peptidase IV ( DPPIV ) inhibitor , SGLT2 inhibitor , amylin . 4 . Chronic use systemic glucocorticoid immunosuppressive agent , biologic immunomodulators within 6 month prior study entry . Specifically , subject receive 7 day treatment 7.5 mg prednisone ( equivalent ) within 6 month prior study entry exclude . 5 . History malignancy ( include squamous cell carcinoma skin cervix ) except adequately treat basal cell carcinoma 6 . Pregnant breastfeed woman , female unwilling use reliable effective form contraception 1 year Treg +/ IL2 dosing , male unwilling use reliable effective form contraception 3 month Treg +/ IL2 dose 7 . Any condition , investigator 's opinion , may compromise study participation may confound interpretation study result . 8 . Patients unwilling agree participate another clinical trial , opinion investigator may confound result study , least 1 year follow Treg infusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Treg</keyword>
</DOC>